Lexeo Therapeutics stock rises after FDA breakthrough designation

Published 07/07/2025, 13:42
© Reuters.

Investing.com -- Lexeo Therapeutics Inc (NASDAQ:LXEO) stock rose 2.3% after the company announced that the U.S. Food and Drug Administration granted breakthrough therapy designation for its Friedreich ataxia treatment.

The FDA designated LX2006, Lexeo’s gene therapy for Friedreich ataxia, as a breakthrough therapy based on interim clinical data showing improvements in cardiac biomarkers and functional measures. Additionally, the FDA selected LX2006 for its Chemistry, Manufacturing, and Controls Development and Readiness Pilot program, which aims to accelerate patient access to therapies.

The breakthrough designation was supported by data from 17 participants across two clinical trials: the company-sponsored SUNRISE-FA Phase 1/2 trial and a Weill Cornell Medicine investigator-initiated Phase 1A trial. Results demonstrated clinically significant improvements in cardiac biomarkers and cardiac and neurologic functional measures, with increased frataxin expression observed in all participants with cardiac biopsies three months after treatment.

Friedreich ataxia is a genetic disorder affecting the nervous system and causing movement problems. The condition typically leads to cardiomyopathy, which is the primary cause of death in patients with the disease.

"We are highly encouraged by the impact of LX2006 on key measures of cardiac health, especially given the lack of treatments for FA cardiomyopathy today, which is the leading cause of death in FA," said Dr. Sandi See Tai, Chief Development Officer of Lexeo Therapeutics.

Stifel analyst Paul Matteis reiterated a Buy rating and $21.00 price target on Lexeo Therapeutics. The analyst commented, "We view receipt of BTD here after the FDA has reviewed clinical data to be a bullish sign for their regulatory prospects--of note this also occurred for SLNO in PWS--and continuing to show that for rare/GTx, FDA may continue to remain flexible/accommodating."

Lexeo is currently enrolling patients in a prospective natural history study called CLARITY-FA, which will serve as a concurrent external control arm for the registrational study expected to begin by early 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.